

Robert Sloane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4362195/publications.pdf>

Version: 2024-02-01

18
papers

6,166
citations

687363

13
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

10436
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	12.8	9
2	Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. <i>Cancers</i> , 2021, 13, 5301.	3.7	7
3	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i> -mutated melanoma. <i>Oncolmmunology</i> , 2021, 10, 1992880.	4.6	7
4	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
5	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5153-5164.	7.0	126
6	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	4.1	24
7	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
8	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , 2015, 33, 679-690.	2.6	43
9	437 PIM kinase inhibitor AZD1208 sensitises SCLC to BH3 mimetic AZD4320. <i>European Journal of Cancer</i> , 2014, 50, 144.	2.8	0
10	Circulating biomarkers in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 323-332.	2.3	56
11	Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. <i>BMC Cancer</i> , 2014, 14, 226.	2.6	13
12	Method validation of circulating tumour cell enumeration at low cell counts. <i>BMC Cancer</i> , 2013, 13, 415.	2.6	20
13	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. <i>Journal of Thoracic Oncology</i> , 2012, 7, 306-315.	1.1	411
14	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 525-532.	1.6	755
15	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. <i>British Journal of Cancer</i> , 2012, 106, 508-516.	6.4	233
16	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1556-1563.	1.6	788
17	Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. <i>American Journal of Pathology</i> , 2011, 178, 989-996.	3.8	386
18	Circulating Tumor Cells, Enumeration and Beyond. <i>Cancers</i> , 2010, 2, 1236-1250.	3.7	42